4:36 PM ET
8-K
Other 8-K Filing
Transcode Therapeutics Other 8-K Filing
TransCode Therapeutics has initiated a formal strategic process to evaluate alternatives for maximizing the value of its oncology portfolio, including its lead Phase 2a candidate TTX-MC138. The company has engaged Tungsten Advisors to explore potential licensing deals, development partnerships, asset sales, or business combinations.
- Counterparty
- Tungsten Advisors